Skip to Content

Johnson & Johnson

JNJ: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$492.00BdmrwVnmwkgw

Johnson & Johnson Earnings: Growth Outlook Slowing After Solid 2023, but Pipeline Holds Upside

Johnson & Johnson reported fourth-quarter results largely in line with our projections, and we are holding firm to our $164 fair value estimate. The stock looks slightly undervalued, as the market is likely not fully appreciating the firm’s long-term potential with pipeline products that also reinforce J&J’s wide moat.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of JNJ so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center